Antengene Shares Groundbreaking Clinical Results at ASCO 2025
Antengene Corporation Limited, a leading global biopharmaceutical company focused on innovative cancer therapies, has recently announced promising clinical results for two of its pioneering therapies aimed at treating solid tumors resistant to checkpoint inhibitors. Presentations will take place during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the potential of its CD73 inhibitor, ATG-037, and the mTORC1/2 inhibitor, ATG-008.
Key Findings from the Clinical Trials
In the ongoing STAMINA-01 study, ATG-037, an oral small molecule CD73 inhibitor, has shown remarkable efficacy when combined with pembrolizumab, MSD's renowned anti-PD-1 therapy. This combination yielded an overall response rate (ORR) of 36.4% with a disease control rate (DCR) of 100% in patients suffering from melanoma who had previously resisted checkpoint inhibitors. Notably, one patient maintained a partial response over two years, highlighting both the effectiveness and safety of the treatment.
Performance in Lung Cancer
For patients with CPI-resistant non-small cell lung cancer (NSCLC), the combination of ATG-037 and pembrolizumab demonstrated an ORR of 22% and a DCR of 67%. These results mark a significant step forward in addressing the challenges of treating solid tumors that resist commonly used therapies.
Updates on ATG-008
ATG-008 has also showcased encouraging results in the TORCH-2 trial, targeting patients with cervical cancer who are resistant to previous anti-PD-1 therapies. This oral dual mTORC1/2 inhibitor, when used alongside toripalimab, achieved an ORR of 22.2% and a DCR of 85.2% in these patients.
Focus on Patient Outcomes
The trial encompassed patients who had undergone at least one line of anti-PD-1 therapy and one line of platinum-based chemotherapy. As of the latest evaluations, 30 patients received treatment showing a median progression-free survival (PFS) of 4.2 months, indicating a potential new avenue for difficult-to-treat cervical cancer cases.
Robust Safety Profiles
Throughout these studies, both therapies exhibited manageable safety profiles, with the majority of treatment-related adverse events (TRAEs) being of grade 1-2 severity. This underscores the commitment of Antengene to not only focus on efficacy but also prioritize patient safety.
Innovative Approaches to Cancer Treatment
ATG-037 is noteworthy for its oral formulation, providing patients with a more convenient option compared to traditional intravenous treatments. Its design effectively addresses the 'hook effect' that often complicates treatment with anti-CD73 monoclonal antibodies, suggesting a more comprehensive approach to T-cell modulation in combating solid tumors.
About Antengene
Antengene Corporation Limited is dedicated to advancing cancer therapies, holding a diverse pipeline of novel therapeutics aimed at treating various forms of hematologic malignancies and solid tumors. With numerous investigational new drug (IND) approvals and new drug applications submitted across Asia Pacific markets, Antengene is positioned as an impactful player in the biopharmaceutical arena.
The company’s vision of "Treating Patients Beyond Borders" drives its mission to innovate and expand access to effective cancer treatments globally.
Frequently Asked Questions
What is Antengene Corporation Limited?
Antengene is a biopharmaceutical company dedicated to the discovery and development of innovative cancer therapies.
What therapies are being presented at ASCO 2025?
Antengene is presenting clinical results for two therapies: ATG-037 and ATG-008, which target solid tumors resistant to common treatments.
What were the results of ATG-037 in the melanoma study?
ATG-037 showed a 36.4% overall response rate and a 100% disease control rate in melanoma patients.
How does ATG-008 perform in cervical cancer patients?
In patients with cervical cancer, ATG-008 achieved a 22.2% overall response rate and an 85.2% disease control rate.
What is the focus of Antengene's ongoing research?
Antengene focuses on creating innovative therapies to tackle hematologic malignancies and solid tumors, offering new hope to patients globally.
